Wai Yuen Tong Medicine Holdings Limited provided earnings guidance for the financial year ended 31 March 2023. For the period, the company expected to record a loss attributable to owners of the parent of not more than HKD 35 million for the financial year ended 31 March 2023 as compared with a loss attributable to owners of the parent for the financial year ended 31 March 2022 of approximately HKD 108.9 million as published in the Company's 2022 annual report.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.23 HKD | +0.44% | 0.00% | -42.50% |
1st Jan change | Capi. | |
---|---|---|
-42.50% | 32.94M | |
+43.96% | 6.34B | |
-15.56% | 4.51B | |
-6.52% | 3.29B | |
+5.47% | 3.2B | |
-0.76% | 2.59B | |
+56.34% | 2.09B | |
-4.11% | 1.76B | |
+2.93% | 1.7B | |
-8.02% | 1.62B |
- Stock Market
- Equities
- 897 Stock
- News Wai Yuen Tong Medicine Holdings Limited
- Wai Yuen Tong Medicine Holdings Limited Provides Earnings Guidance for the Financial Year Ended 31 March 2023